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Importance There is a lack of understanding of what is normal in terms of sex steroid levels 
in older women. 
Objective To determine whether sex steroid levels vary with age in and establish reference 
ranges for women beyond 70 years.  
Design and setting Cross-sectional, community based, study 
Participants 6392 women, aged 70 years and older. 
Main outcome measures Sex steroids measured by liquid chromatography-tandem mass 
spectrometry. A reference group, to establish sex steroid age-specific reference ranges, 
excluded women using systemic or topical sex steroid, anti-androgen or glucocorticoid 
therapy or an anti-glycaemic agent.  
Results The reference group of 5326 women had a mean age of 75·1 (± 4·2) years, range 70-
94·7 years. Median values (range) were estrone (E1)181·2 pmol/L (3·7-5768·9), T 0·38 
nmol/L (0·035-8·56), dehydroepiandrosterone (DHEA) 2·60 nmol/L (0·07-46·85) and SHBG 
41·6 nmol/L (2·4-176·6). Estradiol and dihydrotestosterone were below method sensitivity in 
66·1% and 72·7% of the samples, respectively. Compared with women aged 70-74 years, 
women aged 85+ years had higher median levels of E1 (11·7%, p=0·01), T (11·3%, p=0·02) 
and SHBG (22·7%, p<0·001) and lower DHEA (30% less, p<0·0 1). Overweight and obese 
women had higher E1 (p<0·001) and T (p<0· 3), and lower SHBG (p<0· 01) than women 
with normal body mass index. Smokers had 17·2% higher median  levels (p=0·0 5). 
Conclusion From the age of 70 years, T and E1 increase with age, despite a steady decline in 
DHEA. Whether E1 and T are biomarkers for longevity, or contribute to healthy aging merits 
investigation. 
This study shows estrone and testosterone  increase in women after 70 years and that testosterone 
levels in women aged 70 plus are similar to levels measured in premenopausal women. 
Introduction 
With the steady increase in the life expectancy of older women over the past 4 decades (1), 
understanding the factors that keep women healthy as they age is imperative to reduce the 
number of years lived with disability.   Sex hormones are implicated as having a critical role 
in the development and evolution of age-associated disease, including cardiovascular disease 
and cancer, with the focus mainly on oestrogens in women. Counter-intuitively, testosterone 
(T), which circulates in higher concentrations than estrogens in women of all ages, may be as, 
or even more, important than estrogens in determining disease risk in elderly women (2).  
The first step in advancing the understanding of androgens in older women’s health is 
establishing normal levels in a community-based sample of women. Until now, the available 
data have been limited by small sample sizes and /or the use of direct immunoassays which 
lack sensitivity and specificity for the measurement of testosterone (T) at the concentrations 
occurring in women, compared with the higher levels seen in men (3-6). 
The ASPREE (ASPirin in Reducing Events in the Elderly) Study was a placebo-
controlled randomised clinical trial (RCT) of daily low dose aspirin versus placebo in older 
people, free of cardiovascular disease (CVD) events, with unimpaired cognition at 
recruitment. The large sample of women in this cohort has enabled us to determine whether 
sex steroids vary beyond the age of 70 years and, for the first time, establish age-specific 
reference ranges for each of the main sex steroids for community-dwelling women aged 70 





































































ASPREE was an RCT of aspirin (100 mg enteric coated daily) versus placebo in healthy 
older people. Details of the trial design have been published elsewhere (7,8). In brief, 
Australian recruitment to ASPREE was achieved through partnerships with over 2500 
general practitioners across the southern states of Victoria, South Australia and Tasmania. 
Australian participants were aged at least 70 years. Exclusion criteria included any chronic 
illnesses likely to limit survival to less than 5 years, documented CVD or cerebrovascular 
disease, dementia or a score of <78 on Modified Mini-Mental State Examination (9), 
disability (severe difficulty or inability to perform any of the 6 Katz activities of daily 
living(10)), any condition associated with a high current or recurrent risk of bleeding, 
anaemia or uncontrolled high blood pressure (systolic ≥ 180 mmHg and/or diastolic ≥ 105 
mmHg).  
Clinical parameters 
Date of birth, all concomitant medication use, and smoking and alcohol consumption were 
documented at randomisation.  Clinical measurements included weight, height, waist 
circumference, and systolic and diastolic blood pressure.  
Sex Steroid measurement 
Blood samples were drawn at recruitment (or within 12 months) and plasma stored under 
nitrogen vapour. Sex steroids and SHBG were measured in a single sample of plasma by LC-
MS/MS at the ANZAC Research Institute, University of Sydney. T, dihydrotestosterone 
(DHT), DHEA, estradiol (E2), and E1 were quantified within a single run without 
derivatization as previously described (11) and with modifications (12).  
Briefly, plasma (200 µL) spiked with 50 µL of internal standard (d3-T, d4-E2, d3-DHT, 
d2-DHEA) were extracted with 1 mL of methyl tert-butyl ether, separated by freezing to 
allow removal of the organic layer. After evaporation, the extract was reconstituted in 75 µL 
of 20% methanol so that 50 µL was injected into the LC-MS/MS system. Extracts of 
samples, standards and quality controls were injected into a Shimadzu Nexera ultra-high 
pressure liquid chromatography system comprising a Phenomenex Kinetex 1.7µXB C18 
100A (50x2.1mm) column with a Phenomenex C18 guard cartridge. The elution solvents 
were water (A) and methanol (B). A gradient elution was performed at a flow rate of 0.5 
mL/min with 25% B (0–0.10 min), 52–62% B (0.11–4.30 min), 100% B (4.31–5.45 min), 
25% B (5.46–7.00 min). The column temperature and autosampler were set at 40°C and 4°C, 
respectively. An AB Sciex API 5000 triple quad mass spectrometer was used with 
Photospray (APPI) ion source in positive (androgens) and negative (estrogens) polarity. 
Toluene was used as dopant, delivered at 0.05 mL/min. The ion source, curtain, and collision 
gas was nitrogen. Multiple reaction monitoring was employed with both quadrupoles at unit 
resolution. Two mass transitions were monitored for each analyte (13). Certified reference 
materials were used for assay standards for T, DHT and DHEA (National Measurement 
Institute (NMI), Sydney) and E2 and E1 (Cerillant). Internal standards used were stable 
isotopes - d3-T, d3-DHT and d2-DHEA (NMI), d4-E2 (Cambridge Isotopes). For E1 the 
internal standard d4-E2 was used for quantitation purpose. 
The assay limits of detection, limits of quantification and within-run and between-run 
coefficient of variations (CV) are T (35 pmol/L, 0·09 nmol/L, 2·0%, 3·9-6·5%), DHT (0.17 
nmol/L, 0.34 nmol/L, 8·1%, 6·7-13·4%), E2 (11 pmol/L, 18 pmol/L, 6·6%, 4·8-8·6%), E1
(3·7 pmol/L, 11 pmol/L, 4·7%, 4·6-7·5%) and DHEA (0·07 nmol/L, 0·17 nmol/L, <10%, 
<10%) (14). SHBG was measured in batches by automated immunoassay (Roche 
Diagnostics, Australia) with a CV of 1·0-2·0%.  The median (range) for T and DHEA for 
menstruating, premenopausal women, aged 18-39 years (n=602)(15) performed using the 
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This study was approved by the Monash Human Research Ethics Committee (CF16/10 - 
2016000001) and the Alfred Hospital Human Research Ethics Committee (616/15). All 
participants provided written informed consent to contribute biospecimens to the ASPREE 
Healthy Ageing Biobank. 
Sample size and statistical analysis 
We defined a reference group of women from within the study population to establish 
normative sex steroid values by age. ASPREE participants were excluded from the reference 
group if they were using any of the following at recruitment: any form of systemic or topical 
sex steroid therapy (oestrogen, progestogen, tibolone, dehydroepiandrosterone (DHEA) or 
testosterone), tamoxifen, or other selective oestrogen receptor modulator, aromatase 
inhibitors, anti-androgen therapy (spironolactone or cyproterone acetate), glucocorticoid 
therapy or any anti-glycaemic agent.  
It was anticipated that the distribution of women with recruitment sex steroid values 
measured in the age groups 70 to 74 years, 75 to 79 years, 80 to 84 years and 85 years and 
older would be approximately n=3787, 1840, 824, 268 respectively. The 80 to 84 year strata 
would have adequate precision to estimate sex steroid ranges with the mean estimated with 
95% CI width of + 0·07 standard deviations (SD) and the 2·5th and 97·5th percentiles will be 
estimated with approximate 95% CI widths of + 0·12SD. Means, (SD), medians and 10th to 
90th percentile ranges are reported for each sex steroid in each of the age strata 70 to 74, 75 to 
79, 80 to 84 and 85 years or more. 
The Kruskal Wallis test was used for comparison of the distribution of continuous 
variables across groups and the chi-square test for categorical variables. Linear regression for 
each of E1, T, DHEA and SHBG was done for the ln(analyte) with age, body mass index 
(BMI) and smoking as factors in the model and coefficients exponentiated to have 
interpretation as ratios of adjusted geometric means (with a geometric mean being similar in 
value to a median). 
Results 
Recruitment to ASPREE commenced in 2010 and was completed by December 2014. Of the 
16,703 Australian participants, 9180 (55%) were women. 6392 women had Biobank samples 
available for measurement of sex steroids and SHBG (Figure 1). The characteristics of these 
women and the subset of 5326 women in the reference group are shown in Table 1. The 
included and excluded participants were similar in age, ethnicity, smoking status and blood 
pressure. The included women were aged 70 to 94·7 years and 98·9% were of European 
ancestry. They had a lower mean BMI (28·0 + 5·0 vs 28·6 + 5·0 kg/m2, p=0·001) and smaller 
mean waist circumference than the excluded women (92·6 + 12·5 vs 94·4 + 13·2 cm, 
p=0·001).  
For the 5326 women included in the reference group, E2 and DHT were below the 
sensitivity of the assay method in 3522 (66·1%) and 3873 (72·7%) respectively (Table 2). 
The proportion of women with serum E2 below the measurement limit increased with age 
from 64·8% in 70-74 years to 72·3% in 85+ aged women (p<0·001). The proportion of 
women with serum DHT below the assay sensitivity declined with age from 73·8% in 70-74 
year old women to 58·2% in 85+ age group (p<0·001). For the 1083 women with measurable 
E2 the median value was 22·03 pmol/L (range 11·0 to 1373·0). Because of the relatively 
small numbers of women with values above the assay sensitivity for E2 and DHT, these 
steroid levels were not analysed further. 
Details for E1, total T, DHEA and SHBG by age groups are provided in Table 3, and 
shown graphically in Figure 2. Median steroid values (range) for the total reference group 
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(0·069-46·85) and SHBG 41·6 nmol/L (2·4-176·6). As seen in Figure 2, there were a number 
of outliers for each steroid in each age group. We examined whether any of the measured 
variables (BMI, weight, waist circumference, smoking) and any reported medication use, 
predicted extreme outliers for any of the steroids, but could not identify a common 
explanation for the outliers. 
The following multivariable analysis results are derived from the ratios of adjusted 
geometric means, as described in the methods. Compared with women aged 70-74 years, 
women aged 80-84 and 85+ had higher E1 levels (respectively higher by 9·2%, p=0·001, and 
11·7%, p=0·01). Overweight and obese women had higher E1 l vels than normal weight 
women (respectively higher by 14·6% and 34·1%, p<0·001). T levels were significantly 
higher in women 80-84 years and 85+ years, than women 70-74 years (higher, respectively 
by 9·3%, p=0·004 and 11·3%, p=0.02) (Table 4). Overweight and obese women also had 
higher T levels (5·2%, p=0·03 and 5·5% respectively, p=0·03). Current smokers had 17·2% 
higher T levels than non-smokers (p=0·005). SHBG increased with age from 70-74 years, 
being 5·6% higher in women aged 75-79 years, 13·6% higher in 80-84 years and 22·7% 
higher in 85+ years (p<0·001 for all).  Being overweight was associated with a 15% lower 
SHBG and being obese a 27% lower SHBG level (p<0·001). Current smokers had SHBG 
levels 7·6% higher than non-smokers (p=0·023). In multivariable linear regression, E1 was
not independently associated with SHBG, when BMI and age were taken into account. T was 
independently, positively associated with SHBG (p<0.001) when BMI, age, and smoking 
were included in the model (data not shown). 
DHEA levels showed a steady decline with age such that women aged 85+years had 30% 
less DHEA than women aged 70-74 years (p<0·001). DHEA levels were significantly higher 
in underweight (25% higher, p=0·036) and overweight women (5·2% higher, p=0·032). 
When compared with the reference group, current glucocorticoid users (n=188) had 
significantly lower levels of DHEA (median 1·04 nmol/L, range 0·07-8·61, p=0·0001), T 
(0·024 nmol/L,0·03-1·84, p=0·0001) and E1 (107·1, 3·7-6212·6, p=0·0001). Glucocorticoid 
users had a lower median SHBG of borderline statistical significance (39·2 nmol/L, 1·4-
237·6, p=0·055). 
Discussion 
This large, cross-sectional study of circulating sex steroid levels in older women free of 
severe illness demonstrates small, but steady, increases in circulating T and E1 in women 
from the age of 70 years, despite a steady decline in DHEA and that circulating T levels in 
women aged 70+ years are similar to levels in healthy premenopausal women measured by 
the same assay. This study also highlights the importance of E1 as the major circulating 
oestrogen in older, postmenopausal women and possibly a detrimental impact of 
glucocorticoid use. 
The T levels in the women in this study did not differ from levels seen in premenopausal 
women, measured by the same LC-MS/MS assay, and exhibited a small, but statistically 
significant, difference across age groups. We previously observed, in a study of women aged 
18 to 75 years,  a nadir for total T, measured by sensitive immunoassay, for women between 
62 and 63 years of age, followed by a small increase beyond that in women up to age 75 (3). 
Laughlin et al observed a similar, statistically significant, positive association between T and 
age in their study of women with a mean age of 73.8 years(16).   In contrast, an apparent 
decline in total T, measured by immunoassay, in women between 65 and 80 years was 
reported in a sample of 347 women, mean age of 74 years (6).  Having not included women 
younger than 70 years, the present study neither supports nor refutes our prior observation of 
a nadir in total T in women in their early sixties. It does however establish that T levels in 































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00743 
 
 6
As in younger women, circulating levels of DHEA are several fold greater than that of T (4) 
indicating that biosynthesis of T is dependent on enzyme activity, not precursor availability.  
The determinants of extra-gonadal T biosynthesis by conversion of circulating precursors of 
adrenal origin in women are not known. However, as in our previous study (3), and as has 
been reported for men (17), tobacco smokers had significantly higher T levels than non-
smokers. Whether this is due to an effect of smoking on T biosynthesis, secretion or 
metabolism is not known. 
In postmenopausal women, DHEA and its derivative androstenedione, are the major 
source of circulating E1 through aromatisation of androstenedione in extra-gonadal tissues, 
primarily adipose (18). Adipose aromatase gene expression increases with age in women 
(19,20). Therefore, the capacity for adipose tissue to biosynthesise E1 increases with age.  
The steady increase in E1 levels with increasingly older groups of women in the present 
study, independent of BMI and SHBG is a new finding that indicates aromatase activity 
continues to increase with age even in elderly women. With the loss of ovarian E2 production, 
in postmenopausal women E1 is an important precursor for peripheral E2 biosynthesis, and T 
is further converted to DHT, with both E2 and DHT being further metabolised intra-cellularly 
(18,21). Hence, in the majority of women concentrations of E2 and DHT were below the limit 
of detection, consistent with the intracrine production and metabolism of both hormones 
occurring within the tissues in which they act, with serum levels arising from unregulated 
spill-over from tissues into the circulation (18). 
The increasing proportion of women with unmeasurable E2 in the older groups most 
likely reflects different effects of age on the enzymatic pathways essential for the 
biosynthesis of these hormones. Regardless, a key message from the findings is that studies 
investigating the association between oestrogens and diseases of ageing in postmenopausal 
women, must measure E1 in order to provide meaningful findings. 
The positive association between age and SHBG seen in the present study has previously 
been reported in a study of SHBG across the lifespan (22). As in the present study, we have 
previously reported a positive, independent association between SHBG and T in 
postmenopausal women (23). This most likely reflects the high proportion of circulating T 
that is SHBG bound. SHBG appears to be metabolically important, with low SHBG 
identified as an independent marker of insulin resistance and type 2 diabetes risk (24). SHBG 
has also been implicated in the pathogenesis of type 2 diabetes and CVD (24,25). We have 
previously demonstrated strong, independent and highly statistically significant inverse 
associations between both  insulin resistance, estimated by the homeostasis model of insulin 
resistance, and SHBG, and between BMI and SHBG (23). These associations were 
independent of sex steroids. The greater SHBG levels in older women may reflect a 
metabolic survivorship advantage of women who have higher SHBG.  
Agreeing with previous reports, we found glucocorticoid-users had significantly lower 
levels of T (6), as well as E1 and DHEA than non-users. The low DHEA in glucocorticoid-
users reflects adrenal suppression, but might also be a consequence of their underlying 
disease. This finding does however support the importance of DHEA for E1 and T 
biosynthesis. 
Strengths of this study include the large community-based study sample providing high 
statistical precision for estimating sex steroid ranges. This cohort is likely to be as 
representative as any other healthy volunteer-based study. Measurement of sex steroids by 
gold standard LC-MS/MS is an important study strength. Sensitivity for E2 was a limitation. 
Although a more sensitive method to measure E2 was available, the time and labor-demands 
of the more sensitive technique, it was not feasible for a study of this magnitude. The LC-
MS/MS method used for this study does not allow for androstenedione (analysed in positive 































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00743 
 
 7
two steroids elute at virtually the same retention time. Our method includes fast polarity 
switching but cannot cope with co-eluting compounds with opposite polarity.  However, in 
postmenopausal women virtually all androstenedione is of adrenal origin. Therefore, its 
parent steroid DHEA provides a strong overall index of adrenal androgen production. 
 Our earlier study(3) and that of  Cappola et al(6) reported much higher T levels in older 
women than measured with LC-MS/MS in the present study, consistent with known issues of 
cross-reactivity and less specificity of the older RIAs used previously  (26,27). To explore the 
physiology of ageing, we excluded women who reported use of medications that would 
influence sex steroid measurement or metabolism. We excluded women taking anti-
glycaemic medications in order to rule out women with type 2 diabetes requiring treatment, 
in order to minimise the effects of insulin resistance on sex steroid levels through effects on 
SHBG. A number of women in the reference group had sex steroid levels suggestive of 
exogenous hormone use. We examined all medication use in the outliers for each steroid to 
exclude any unexpected cross-re-activity in assays and found none. Although the higher sex 
steroid levels found in a few women did not fit our expectations, without evidence of 
exogenous steroid use, we could not justify their exclusion from the analysis. This decision is 
supported by prior smaller studies that have reported unexpectedly high estrone and androgen 
levels in otherwise well postmenopausal women (3,6,28-30). The high levels observed in 
some women in our study re-affirm the wide range of ‘normality’ within a community-based 
population, and support the representativeness of our study sample. A limitation of our study 
is that we are inferring the association between hormone levels and age from cross-sectional 
data. Whereas the optimal study design would be longitudinal, it would be prohibitively 
difficult and vulnerable to attrition bias. Our sample being mostly of European ancestry 
matches that of the Australian population of this age (31). However, our findings cannot be 
extrapolated to women of non-European ancestries. Information about past hysterectomy or 
oophorectomy was not collected, such that the impact of oophorectomy on hormone levels in 
older women could not be examined. 
In summary, we have successfully established normal ranges for sex steroids in women 
aged 70 years and above. Important observations are that in women aged 70+ years 
circulating T levels do not differ meaningfully from those of premenopausal women, and 
together with E1, appear to increase from the age of 70 years. Concurrently DHEA levels 
exhibit a progressive decline from the age of 70 years. E1, T and SHBG may be biomarkers 
for longevity, or contribute to healthy ageing.  
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Figure 1. Flow chart of study participants. Footnote. *not including women who reported 
estrogen use 
Figure 2 Relationship between age and individual sex steroids for the reference group. 
Footnote. In the box and whisker plots (outliers not included), the box represents the 
interquartile range (IQR), the line in the box is the median. The whiskers extend to the upper 
and lower adjacent values. The upper adjacent value is defined as the largest data point <= 
the 75th percentile + 1·5 X IQR. The lower adjacent value is defined as the smallest data 
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raw data are represented as scatter-graphs with fitted LOWESS curves on a log (base 10) 
scale. DHEAS, dehydroepiandrosterone-sulphate; SHBG, sex hormone binding globulin. 
Table 1: Descriptive statistics of women included in, and excluded from the reference group. 
 Included in analysis (n= 5326, 
83.3 %) 
Excluded from analysis (n= 1066, 
16.7%) 
p value 
Age (years)     
Mean (SD), range 75·1 (4·2), 70- 94·7 75·0 (4·2), 70·2 -91·7  
   70-74, n (%) 3122 (58·6%) 654 (61·45) 0·25 
   75-79, n (%) 1442 (27·1%) 257 (24·1%)  
   80-84, n (%) 592 (11·1%) 121 (11·4%)  
   > 85, n (%) 170 (3·2%) 34 (3·2%)  
Ethnicity, n (%)   0·61 
European 5267 (98·9%) 1053 (98·8%)  
Asian 30 (0·6%) 8 (0·7%)  
Aboriginal/Torres Strait Islander 5 (0·1%) 2 (0·2%)  
Other 24 (0·4%) 3 (0·3%)  
Smoking status, n (%)   0·37 
   Current 156 (2·93%) 23 (2·16%)  
   Former 1683 (31·60%) 344 (32·27%)  
   Never 3487 (65·47%) 699 (65·57%)  
Weight  (kg), mean (SD) 71·0 (13·3) 72·6 (13·9) 0·0005 
Height (cm) mean (SD) 1·59 (0·061) 1·59 (0·058) 0·77 
Body mass index (kg/m2),  mean (SD)    28·0 (5·0) 28·6 (5·3) 0·001*  
  < 18.5 , n (%) 46 (0·87%) 7 (0·66%) 0·005#  
18.5 to <25, n (%) 1533 (28·91%) 277 (26·01%)  
25 to <30, n (%) 2128 (40·13%) 402 (37·75%)  
≥ 30, n (%) 1596 (30·10%) 379 (35·59%)  
Waist circumference (cm) mean (SD) 92·6 (12·5) 94·4 (13·2) <0·001 
Systolic blood pressure (mmHg), mean (SD) 141 (18) 141 (18) 0·71 
Diastolic blood pressure (mmHg), mean 
(SD) 
78 (11) 77 (11) 0·18 
*Kruskal Wallis ; # χ2. 
Table 2.  Proportion of women with measurable sex steroid levels by age  
Age grouping (years) 70 to 74 75 to 79 80 to 85 > 85 Total 
Estrone       
Result available 3093 (99·1%) 1425 (98·8%) 589 (99·5%) 170 (100·0%) 5277 (99·1%) 
Below LOD 29 (0·9%) 17 (1·2%) 3 (0·5%) 0 (0·0%) 49 (0·9%) 
Estradiol       
Result available 1097 (35·2%) 480 (33·3%) 179 (30·2%) 47 (27·7%) 1803 (33·9%) 
Below LOD 2024 (64·8%) 962 (66·7%) 413 (69·8%) 123 (72·3%) 3522 (66·1%) 
Total testosterone       
Result available: 3073 (98·4%) 1417 (98·3%) 588 (99·3%) 170 (100·0%) 5248 (98· ·5%) 
Below LOD 49 (1·6%) 25 (1·7%) 4 (0·7%) 0 (0·0%) 78 (1·5%) 
DHT       
Result available 817 (26·2%) 390 (27·1%) 175 (29·6%) 71 (41·8%) 1453 (27·3%) 
Below LOD 2305 (73·8%) 1052 (72·9%) 417 (70·4%) 99 (58·2%) 3873 (72·7%) 
DHEA       
Result available 3107 (99·5%) 1424 (98·8%) 590 (99·7%) 170 (100·0%) 5291 (99·3%) 
Not detected 15 (0·5%) 18 (1·2%) 2 (0·3%) 0 (0·0%) 35 (0·7%) 
SHBG       
Result available 3113 (99·8%) 1441 (99·9%) 592 (100·0%) 169 (100·0%) 5315 (99·9%) 
Below LOD 5 (0·2%) 1 (0·1%) 0 (0·0%) 0 (0·0%) 6 (0·1%) 
LOD, Limit of detection; DHT, dihydrotestosterone; DHEA, dehydroepiandrosterone; SHBG, sex hormone 
binding globulin. # 1 sample missing; ## 5 missing samples. 
Table 3·  Sex steroids by age group in the reference group of women  
Age (years) 70 to 74 75 to 79 80 to 85 > 85 Total 
Estrone, n (pmol/L)*   3093 1425 589 170 5277 
Mean (SD) 210·8 (214·2) 213·7 (194·3) 220·1 (114·9) 223·4 (121·5) 213·0 (197·6) 
Median 181·2 181·2 196·0 205·2 181·2 
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10th centile 88·7 85·0 99·8 83·2 88·7 
90th centile 340·2 351·3 362·4 369·8 347·6 
Maximum 5768·9 4733·4 894·9 717·4 5768·9 
Testosterone, n 
(nmol/L) †  
3073  1417 588 170 5248 
Mean (SD) 0·45 (0·45) 0·46 (0·37) 0·49 (0·44) 0·52 (0·50) 0·47 (0·43) 
Median 0·35 0·35 0·38 0·38 0·38 
Minimum 0·03 0·03 0·03 0·03 0·03 
10th centile 0·17 0·17 0·17 0·17 0·17 
90th centile 0·76 0·87 0·90 1·11 0·83 
Maximum 8·56 4·75 5·37 4·16 8·56 
DHEA, n  (nmol/L)  †     3107 1424 590 170 5291 
Mean (SD) 3·25 (2·19) 3·02 (2·20) 2·87 (1·99) 2·35 (1·61) 3·11 (2·16) 
Median 2·74 2·50 2·32 2·05 2·60 
Minimum 0·07 0·07 0·07 0·07 0·07 
10th centile 1·11 0·94 0·97 0·82 1·04 
90th centile 6·11 5·73 6·07 4·15 6·00 
Maximum 46·85 27·38 10·03 9·82 46·85 
SHBG, n (nmol/L)    3113 1441 592 169 5315 
Mean (SD) 42·9 (18·2) 45·5 (19·3) 49·3 (19·5) 54·6 (21·9) 44·7 (19·0) 
Median 39·8 42·8 46·3 51·5 41·6 
Minimum 2·8 2·4 13·4 16·6 2·4 
10th centile 23·5 24·3 27·2 29·4 24·2 
90th centile 66·2 70·0 75·2 83·2 68·9 
Maximum 167·6 151·2 155·3 124·2 167·6 
 †To convert nmol/L to ng/dL or pmol/L to pg/dL divide by 0·0347; ††to convert nmol/L to ng/dL divide by 
0·0344; *to convert pmol/L to pg/ml, divide by 3·67  
DHT, dihydrotesosterone; DHEA, dehydroepiandrosterone; SHBG, sex hormone binding globulin; SD, standard 
deviation·  
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